Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection.

Tomokazu OhishiTohru MasudaHikaru AbeChigusa HayashiHayamitsu AdachiShun-Ichi OhbaMasayuki IgarashiTakumi WatanabeHitomi MimuroEri AmaliaDaniel Ken InaokaKota MochizukiKiyoshi KitaMasakatsu ShibasakiManabu Kawada

Published in: Helicobacter (2018)

AS-1934 has potential advantages over current treatment options for H. pylori infection.

Keyphrases

helicobacter pylori infection
helicobacter pylori
combination therapy
open label
randomized controlled trial
clinical trial
climate change
study protocol
human health